Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Izutsu, Koji [1 ]
Goto, Hideki [2 ]
Kizaki, Masahiro [3 ]
Yamaguchi, Masaki [4 ]
Fukuhara, Noriko [5 ]
Kato, Koji [6 ]
Saito, Toko [7 ]
Terui, Yasuhito [8 ]
Okubo, Sumiko [9 ]
Soshin, Tomomi [9 ]
Mukherjee, Nabanita [10 ]
Honda, Hideyuki [9 ]
Badawi, Mohamed [10 ]
Ross, Jeremy [10 ]
Ishizawa, Kenichi [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hokkaido Univ Hosp, Hokkaido, Japan
[3] Saitama Med Ctr, Saitama, Japan
[4] Ishikawa Prefecture Cent Hosp, Kanazawa, Ishikawa, Japan
[5] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[6] Kyushu Univ Hosp, Fukuoka, Japan
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Saitama Med Univ Hosp, Saitama, Japan
[9] Abbvie GK, Tokyo, Japan
[10] AbbVie Inc, N Chicago, IL USA
[11] Yamagata Univ Hosp, Yamagata, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO50-5
引用
收藏
页码：S1428 / S1428
页数：1
相关论文
共 50 条
  • [21] Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Kamal
    Cartron, Guillaume
    Casasnovas, Olivier
    Gastinne, Thomas
    Chevallier, Patrice
    Rossi, Cedric
    Tchernonog, Emmanuelle
    McCulloch, Rory
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2019, 134
  • [22] Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
    Tam, Constantine S.
    Anderson, Mary Ann
    Pott, Christiane
    Agarwal, Rishu
    Handunnetti, Sasanka
    Hicks, Rodney J.
    Burbury, Kate
    Turner, Gillian
    Di Iulio, Juliana
    Bressel, Mathias
    Westerman, David
    Lade, Stephen
    Dreyling, Martin
    Dawson, Sarah-Jane
    Dawson, Mark A.
    Seymour, John F.
    Roberts, Andrew W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (13): : 1211 - 1223
  • [23] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 20 - 21
  • [24] Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca
    Bishop, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2020, 61 : 227 - 228
  • [25] Ibrutinib in refractory mantle cell lymphoma or relapsed data update
    Paillassa, Jerome
    HEMATOLOGIE, 2015, 21 (05): : 257 - 259
  • [26] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04): : 361 - 368
  • [27] IBRUTINIB PLUS WITH VENETOCLAX FOR THE TREATMENT OF PRIMARY REFRACTORY MANTLE-CELL LYMPHOMA: A REAL LIFE EXPERIENCE
    Fabbri, A.
    Cencini, E.
    Congiu, A. G.
    Miglino, M.
    Rigacci, L.
    Bocchia, M.
    HAEMATOLOGICA, 2019, 104 : 161 - 161
  • [28] Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Herrera, Alex Francisco
    Armenian, Saro H.
    Mei, Matthew
    Popplewell, Leslie
    Fueger, Abbey
    Qasim, Imran
    Stiller, Tracy
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    BLOOD, 2017, 130
  • [29] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [30] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
12345